Carbapenem derivatives
An objective of the present invention is to provide carbapenem derivatives which have strong antibiotic activity also against MRSA, PRSP, Influenzavirus, and β-lactamase producing bacteria and are stable to DHP-1. The carbapenem derivatives according to the present invention are compounds represented by formulae (I) and (II) or pharmaceutically acceptable salts thereof: wherein R 1 represents H or methyl, R 2 and R 3 each independently represent H; halogen; substituted or unsubstituted alkyl; cycloalkyl; substituted or unsubstituted alkylcarbonyl; carbamoyl; substituted or unsubstituted aryl; substituted or unsubstituted alkylthio; morpholinyl; alkylsulfonyl; or formyl, n is 0 (zero) to 4, and Hy represents a substituted or unsubstituted monocyclic or bicyclic heterocyclic group.
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
wherein R 1 represents a hydrogen atom or methyl,
R 2 and R 3 represent a hydrogen atom,
n is 0 (zero), and
Hy represents pyridinium-3-yl which is substituted by carbamoyl lower alkyl, carboxyl lower alkyl, or aminosulfonylamino lower alkyl at its 1-position and is optionally substituted by amino lower alkylthio at other than the 1-position.
2. The compound according to claim 1 , wherein R 1 represents methyl, R 2 and R 3 represent a hydrogen atom, n is 0 (zero), and Hy represents 1-carbamoylmethylpyridinium-3-yl.
3. The compound according to claim 1 , wherein R 1 , R 2 and R 3 represent a hydrogen atom, n is 0 (zero), and Hy represents 1-carbamoylmethylpyridinium-3-yl.
4. The compound according to claim 1 , wherein R 1 represents methyl, R 2 and R 3 represent a hydrogen atom, n is 0 (zero), and Hy represents 1-carboxymethylpyridinium-3-yl.
5. The compound according to claim 1 , wherein R 1 represents methyl, R 2 and R 3 represent a hydrogen atom, n is 0 (zero), and Hy represents 1-(2-aminosulfonylaminoethyl)pyridinium-3-yl.
6. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition according to claim 6 , which further comprises pharmaceutically acceptable adjuvants.
8. A method for treating bacterial infection, comprising the step of administering a therapeutically effective amount of the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
9. The method according to claim 8 , wherein the mammal is a human.